Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug side effect under the microscope: muscle enzyme spike studied

NCT ID NCT01248429

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels were linked to muscle pain. The goal was to better understand this side effect, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

154 people

The number who actually took part.

Started

Nov 2010

Finished

Jan 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated for a solid tumor by thyrosin kinase inhibitors

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week * Patient examined AND with a routine blood test planned * Patient informed of procedure for the study who was not opposed to it Exclusion Criteria: * Patient treated for malignant hemopathy * Patient no treated by inhibitor of thyrosine kinase or for less than 1 week * Patients with no routine blood laboratory tests planned

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Myalgia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Solid tumor

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, 33076, France

  • CHU Limoges

    Limoges, 87042, France

  • CHU Robert Debré

    Reims, 51092, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54511, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Henri Becquerel

    Rouen, 76000, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Léon Bérard

    Lyon, 69008, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Paul Papin

    Angers, 49000, France

  • Centre René Huguenin

    Saint-Cloud, 92211, France

  • Centre Val d'Aurelle

    Montpellier, 34298, France

  • Hôpital Cochin - APHP

    Paris, 75014, France

  • Hôpital Edouard Herriot

    Lyon, 69003, France

  • Hôpital Henri Mondor - APHP

    Créteil, 94010, France

  • Hôpital Jean Minjoz

    Besançon, 25030, France

  • Hôpital Saint-Louis - APHP

    Paris, 75010, France

  • Hôpital Tenon - APHP

    Paris, 75020, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Claudius Régaud

    Toulouse, 31052, France

  • Institut Curie

    Paris, 75248, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Jean Godinot

    Reims, 51056, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Institut de Cancérologie de la Loire

    Saint-Priest-en-Jarez, 42271, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.